Health productsUpdated Jan 3, 2026ALBRIOZAOfficial source

    ALBRIOZA recall in Canada: Market withdrawal

    Share:

    In plain language

    This recall involves ALBRIOZA (sodium phenylbutyrate and ursodoxicoltaurine) sold in Canada. It's being withdrawn from the market because a recent study did not confirm its clinical benefit for treating ALS. Patients should discuss their treatment with their healthcare professional.

    What to do

    • Do not start ALBRIOZA if you are a new patient.
    • If you are currently using ALBRIOZA, discuss with your healthcare professional whether to continue treatment.
    • Report any side effects to Amylyx Pharmaceuticals, Inc. or Health Canada.

    Get alerts for recalls like this

    Get email alerts when new recalls affect products in this category.

    Categories (optional)

    No spam. Unsubscribe anytime. We only email when there's a relevant recall.

    Affected products

    • ALBRIOZA (sodium phenylbutyrate and ursodoxicoltaurine)

    Do I have this product?

    This recall only applies to specific products. Follow the steps below to check.

    1. 1

      Check the product name

      Make sure your product name matches one of the affected products listed above.

    If your product matches one or more of the details above, it may be affected by this recall.

    If your product does not match these details, it is not affected by this recall.

    When in doubt, always check the official notice.

    Want alerts if similar products are recalled in Canada?

    Frequently Asked Questions

    Why was this product recalled?

    This recall involves ALBRIOZA (sodium phenylbutyrate and ursodoxicoltaurine) sold in Canada. It's being withdrawn from the market because a recent study did not confirm its clinical benefit for treating ALS. Patients should discuss their treatment with their healthcare professional.

    What should consumers do?

    Do not start ALBRIOZA if you are a new patient. If you are currently using ALBRIOZA, discuss with your healthcare professional whether to continue treatment. Report any side effects to Amylyx Pharmaceuticals, Inc. or Health Canada.

    Where was the product sold?

    This product was sold in Canada. For specific retailers or distribution areas, please check the official recall notice linked on this page.

    Is there a health risk?

    A potential safety risk has been identified with this product. Stop using it immediately and follow the instructions in the official recall notice.

    When was this product recalled?

    This product was recalled on June 7, 2024.

    Is the ALBRIOZA brand affected by this recall?

    Yes, ALBRIOZA products are affected by this recall. This recall involves ALBRIOZA (sodium phenylbutyrate and ursodoxicoltaurine) sold in Canada. It's being withdrawn from the market because a recent study did not confirm its clinical benefit for treating ALS. Patients should discuss their treatment with their healthcare professional.